NCT04214860View on ClinicalTrials.gov

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Myeloid Malignancy
Interventions
DRUG

APR-246

APR-246 4.5 g/day

DRUG

Venetoclax

Venetoclax 400 mg once daily

DRUG

Azacitidine

Subcutaneous injection, or intravenous infusion

Trial Locations (8)

10021

Weill Cornell Cancer Center, New York

10065

Memorial Sloan Kettering CC, New York

33612

H. Lee Moffitt CC, Tampa

60611

Northwestern Medicine, Chicago

60637

University of Chicago Medicine, Chicago

77030

MD Anderson Cancer Center, Houston

06511

Yale Cancer Center, New Haven

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Aprea Therapeutics
All Listed Sponsors
lead

Aprea Therapeutics

INDUSTRY

NCT04214860 - APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | Biotech Hunter | Biotech Hunter